Advertisement

Topics

Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

03:35 EDT 20th September 2017 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 16,000+

Extremely Relevant

[Articles] TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

TAS-102 plus bevacizumab has promising activity with manageable safety, suggesting that this combination might become a potential treatment option for patients with metastatic colorectal cancer in a refractory setting.


Effect of Adding Cetuximab vs Bevacizumab to Chemotherapy for KRAS Wild-Type Colorectal Cancer

This randomized clinical trial compares the effect of adding bevacizumab vs cetuximab to standard chemotherapy regimens on overall survival among patients with advanced or metastatic KRAS wild-type colorectal cancer.

Clinical advances in treating colorectal cancer

Prof Geißler speaks with ecancer at ESMO 2017 about recent trials in treating colorectal cancer presented at the congress. He notes the Prodige 18 trial of bevacizumab and the Tricolore trial of combination therapy as stand-out presentations. Prof...


Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer No Difference, but Not the Same

In the United States in 2017, there are projected to be 135 430 individuals newly diagnosed with colorectal cancer and 50 260 deaths from the disease with 18% to 22% having distant metastatic diseases at the time of diagnosis. Over the past decade or more, significant effort has been devoted to optimize first-line treatment for advanced and metastatic colorectal cancer. It has been established...

The Growing Challenge of Young Adults With Colorectal Cancer

n this review, we address specific issues pertaining to AYA patients with colorectal cancer, including evaluation for hereditary colorectal cancer syndromes, clinicopathologic and biologic features unique to AYA patients with colorectal cancer, treatment outcomes, and survivorship.

Cetuximab vs. Bevacizumab for KRAS Wild-Type Advanced Colorectal Cancer

Survival was similar with either agent when combined with first-line chemotherapy.

[Comment] New perspectives for TAS-102: TASK successful?

The US Food and Drug Administration and European Medicines Agency have granted approval to TAS-102 for the treatment of refractory metastatic colorectal cancer.1,2 In The Lancet Oncology, Yasutoshi Kuboki and colleagues report on the results of C-TASK FORCE,3 a phase 1/2 study on the combination of TAS-102 with bevacizumab. The rationale for this study was sound and strong. Phosphorylated trifluri...

[Articles] Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

The benefit conferred by incorporation of bevacizumab is sustained with extended follow-up as evidenced by the overall survival curves remaining separated. After progression while receiving bevacizumab, we did not observe a negative rebound effect (ie, shorter survival after bevacizumab is stopped than after chemotherapy alone is stopped). These findings represent proof-of-concept of the efficacy ...

Adjuvant Bevacizumab for Triple-Negative Breast Cancer

Adding bevacizumab to chemotherapy failed to improve 5-year overall survival.

Bevacizumab Improves Responses, PFS in Advanced Head and Neck Cancer

This video highlights results of a phase III randomized trial that tested chemotherapy plus bevacizumab in patients with recurrent or metastatic head and neck cancer.

Advancing precision medicine in colorectal cancer

Colorectal cancer (CRC) exemplifies the steady progress we’ve made in cancer prevention and treatment,…

FDA Approves Amgen and Allergan’s Mvasi for the Treatment of Five Types of Cancer

THOUSAND OAKS, Calif., Sept. 14, 2017 /PRNewswire/ — Amgen (NASDAQ: AMGN) and Allergan plc. (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved MVASI™ (bevacizumab-awwb) for all eligible indications of the reference product, Avastin® (bevacizumab). MVASI is the first anti-cancer biosimilar, as well as the first bevacizumab biosimilar, approved...

First biosimilar to treat cancer approved by FDA

The US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab-awwb) as a biosimilar to the cancer treatment Avastin (bevacizumab). This represents the first biosimilar approved by the regulatory body for cancer treatment.

FDA approves first-ever biosimilar for cancer treatment

The FDA has announced the news that it has awarded approval to the first-ever biosimilar for the treatment of cancer in the US – Amgen’s Mvasi (bevacizumab-awwb), a biologic version of Genetech’s Avastin (bevacizumab). The drug is approved as a therapy for colon, lung, brain, kidney and cervical cancers. These include: read more

More young people are getting colorectal cancer. What do we do?

After years of declining rates of colorectal cancer (CRC), a study from the American Cancer Society raises the specter that not all is going as well as we would have hoped, especially among younger folks born since 1990. And that raises the question of what the future holds for this frequently preventable form of cancer, […]

Novartis, Bristol-Myers Squibb evaluate potential metastatic colorectal cancer treatments

Colorectal cancer is the third most common type of cancer in men and the second most common in women, with approximately 1.4 million new diagnoses in 2012. For the same period, approximately 694,000 deaths worldwide were attributed to colorectal cancer. Healthcare solutions provider Novartis is working with pharma company Bristol-Myers Squibb to investigate the safety, [&hellip

Possible Breakthrough in Colorectal Cancer Drug Development Cited

NewsStemSynergy announces breakthrough in colorectal cancer drug development. Scientists showed that a novel class of Wnt inhibitors, CK1alpha agonists, blocked colorectal cancer growth with minimal gastrointestinal toxicity.

Colorectal cancer death rates rising in people under 55

(American Cancer Society) A new report finds that colorectal cancer mortality rates have increased in adults under 55 since the mid-2000s after falling for decades.

FDA OKs First 'Biosimilar' Drug to Fight Cancer

THURSDAY, Sept. 14, 2017 -- The first approval of a biosimilar drug to treat cancer was announced Thursday by the U.S. Food and Drug Administration. Mvasi (bevacizumab-awwb) was approved as a biosimilar to Avastin (bevacizumab) for the treatment of...

Bevacizumab Does Not Improve Response, Survival in Ovarian Cancer

Adding bevacizumab to neoadjuvant chemotherapy did not improve complete macroscopic response rate or progression-free survival in women with ovarian cancer.

Comparison of the efficiency of colorectal cancer screening programs based on age and genetic risk for reduction of colorectal cancer mortality

US FDA approves Mvasi for treatment of five types of cancer

Amgen and Allergan have announced that the US Food and Drug Administration (FDA) has approved Mvasi (bevacizumab─awwb) for all eligible indications of the reference product, Avastin (bevacizumab).

New Molecular Test Identifies Colorectal Cancer

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide, with more than 600,000 deaths each year. Among...

Streptococcus Gallolyticus Spurs Colorectal Tumor Growth in Mice – The Scientist

The ScientistStreptococcus Gallolyticus Spurs Colorectal Tumor Growth in MiceThe ScientistBRYAN SATALINOScientists have long known of the link between the bacteria Streptococcus gallolyticus and colorectal cancer (CRC) in humans—numerous case studies have reported instances of patients with S. gallolyticus infections who also have CRC.Bacterium promotes colorectal tumor growthMedical News TodayB...

FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin

September 14, 2017 -- The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is the first biosimilar approved in the U.S. for the...


Quick Search
Advertisement
 

News Quicklinks